My Healthcare News & Research — January 10, 2026

Fat or Muscle? A Large New Study Weighs What You Actually Lose on GLP-1 Drugs and After Surgery

For three years the biggest question hanging over the new weight-loss era has not been whether drugs like semaglutide and tirzepatide — the active ingredients in Ozempic, Wegovy, Mounjaro and Zepbound — take weight off. They plainly do. The question is what kind of weight. Every pound lost is some mix of fat and fat-free mass (the muscle, bone, organ and water that make up everything that is not fat), and losing too much muscle is a real worry, especially for older adults and women. A study published January 9, 2026 in JAMA Network Open is one of the largest real-world looks yet at exactly that trade-off, comparing body-composition changes after GLP-1 drugs versus after bariatric surgery.

What the researchers did

The team — led by Zicheng Wang with senior author Danxia Yu at Vanderbilt University Medical Center — ran a retrospective cohort study using electronic health records from a single U.S. academic medical center. They followed 1,257 adults who had bariatric surgery and 1,809 adults treated with a GLP-1 receptor agonist (semaglutide or tirzepatide) for 24 months. Both groups were roughly four-fifths women (82.2% and 80.5%) with mean ages in the mid-40s. Body composition — fat mass (FM) and fat-free mass (FFM) — was estimated using bioelectrical impedance analysis (BIA). The metric that carries the message is the FFM-to-FM ratio: a higher ratio means a leaner body composition, and a rising ratio is what you want to see, because a higher proportion of lean mass is associated with lower mortality.

What it actually found

Over 24 months, both approaches moved body composition in the favorable direction — fat fell much faster than lean mass:

Because fat came off far faster than lean tissue in both groups, the FFM/FM ratio rose in both — to about 2.0 after surgery and 1.5 with GLP-1 drugs — the signature of a body that is not merely lighter but better composed.

The most clinically interesting result was a sex gap. Men preserved fat-free mass better than women, and the difference was starkest for the drugs. After surgery, fat-free mass accounted for 19.9% of total weight lost in women versus only 10.6% in men at 12 months — women gave up nearly twice as large a share of their weight loss as lean tissue.

What it means

The reassuring take-home is that neither GLP-1 drugs nor surgery, in this dataset, produced the catastrophic muscle wasting that early critics feared. Some fat-free-mass loss is normal and even appropriate when the body gets smaller — you need less structural tissue and water to carry less weight. What matters is proportion, and in both groups fat loss dominated. But the sex difference is a genuine signal: women, who make up the large majority of people taking these drugs, appear to sacrifice a larger fraction of lean mass. Over time that can lower resting metabolic rate, erode strength, and make weight regain easier. It argues for pairing weight-loss treatment with the two interventions best known to protect muscle — resistance training and adequate dietary protein — rather than relying on the drug or the operation alone.

The honest caveats

This is not a head-to-head trial, and the numbers should not be read as “surgery beats drugs.” It was retrospective and observational: the two groups were different people who chose (or were selected for) different treatments, and surgical patients typically start heavier and lose far more total weight, which inflates every surgical percentage. Body composition was estimated by bioelectrical impedance, not measured with the gold-standard DXA scan or MRI; BIA is convenient but less precise and cannot cleanly separate skeletal muscle from other lean tissue and body water. And the data came from a single academic medical center, so the exact figures may not transfer to other populations. The authors themselves note that more work is needed to see how these changes play out in real-world care.

The takeaway

For anyone using or considering a GLP-1 drug or weight-loss surgery, the message is cautiously good: both reshape the body toward a healthier fat-to-lean balance, not just a lower number on the scale. But muscle is not guaranteed. If you are losing weight — especially if you are a woman or over 50, when age-related muscle loss (sarcopenia) is already in play — protect your lean mass deliberately: do resistance work a few times a week, and keep protein intake high enough to support it. The drug does the fat loss; you have to do the muscle keeping.

Sources